The power of combined glycemic control using oral anti-hyperglycemia medications and PI3K inhibitors was shown in the key study “SOLAR-1” of alpelisib in patients with PIK3CA-mutated hormone receptor positive breast cancer which led to improved progression-free survival and the FDA approval of alpelisib [47]. This evidence concerns the gene PIK3CG and Hyperglycemia.